You searched for "cancer"

659 results found

Bladder cancer: where are we with intravesical therapies?

In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...

Recent advances in the management of castration resistant prostate cancer

Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

Bladder cancer outcomes in patients with spina bifida

These authors carried out a systematic review using PubMed and a number of terms to pick up studies with an underlying diagnosis of myelomeningocele and bladder cancer, with exclusions of cord injury, tuberculosis, schistosomiasis, or prior ureterosigmoidostomy. Their aim was...

The role of PET-CT imaging in prostate cancer

Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...

Results of HoLEP in patients with prostate cancer and LUTS

Holmium laser enucleation of the prostate (HoLEP) is recommended for the management of benign prostatic obstruction. With similar functional outcomes and less morbidity compared to transurethral resection of the prostate (TURP), it has become a useful tool in the armament...

Active surveillance for intermediate-risk prostate cancer

In this review, Klotz and Dall’Era summarise available data from the Toronto, UCSF, ERSPC, PASS and Royal Marsden active surveillance cohorts, looking specifically at outcomes of patients classed as intermediate risk. Cancer specific survival in men managed initially with active...

Patient-reported outcomes after prostate cancer treatment

This study used the survivorship (LIVESTRONG) care plan tool to identify patient-reported toxicities that occurred following treatment for prostate cancer. All patients had undergone treatments, which were considered to have similar oncological endpoints. The tool asked patients questions with regard...

Use of MRI in the evaluation of prostate cancer: part 1

Introduction Prostate cancer remains the most commonly diagnosed cancer in males and the second leading cause of cancer related deaths in UK men, after lung cancer [1]. The incidence of prostate cancer in the UK has shown a rapid increase...

Indication to pelvic lymph nodes dissection for prostate cancer

This paper explored the role of multiparametric MRI (mpMRI) in predicting the likelihood of lymph node invasion in patients with a risk of <5% according to the Briganti nomogram. Three hundred and ten patients who underwent a preoperative mpMRI and...

Use of MRI in the evaluation of prostate cancer: part 2

Diffusion weighted imaging and contrast enhanced imaging Introduction Magnetic resonance imaging (MRI) is widely used in localisation, staging and post-treatment follow-up of prostate cancer. In the previous issue, we discussed the usefulness of MRI in depicting prostate anatomy and pairing...

Testicular cancer: management of stage I seminoma

Introduction Testicular cancer is the most frequently occurring solid tumour in men between the ages of 15 and 34 years [1]. About 60% of cases are seminomas and approximately 70-80% of them have, at presentation, clinical stage I disease. This...

Prostate Cancer Diagnosis – PSA, Biopsy and Beyond

The danger of many of the texts which deal with this rapidly changing field is that by the time the texts are published they are out of date. This book however remains fresh, in part because it acknowledges that there...